PROX1: Key Regulator of TGF-β and Cell Adhesion (G5629)

Target Name: PROX1

NCBI ID: G5629

PROX1

PROX1: Key Regulator of TGF-β and Cell Adhesion

PROX1 (OTTHUMP00000035023) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and blood vessels. It is a key regulator of cell signaling pathways, and its dysfunction has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of PROX1 is its role in cell signaling pathways, particularly the TGF-β pathway. TGF-β is a critical signaling pathway that regulates cell growth, differentiation, and survival, and is involved in the development and maintenance of tissues and organs. The TGF-β pathway is activated by a variety of factors, including growth factors, mechanical stress, and chemicals, and its activity is regulated by a number of proteins, including PROX1.

In addition to its role in TGF-β signaling, PROX1 is also involved in the regulation of cell adhesion and migration. It is a critical regulator of the cadherin protein, which is involved in cell-cell adhesion, and is involved in the migration of cells through tissues and organs.

The dysfunction of PROX1 has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that PROX1 is often overexpressed in a variety of cancer types, and that its activity is associated with the development and progression of these diseases. Similarly, research has suggested that PROX1 is involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its role in disease, PROX1 is also a potential drug target. Researchers have identified a number of small molecules that are capable of inhibiting the activity of PROX1, and are in the process of testing these compounds for use in the treatment of various diseases. For example, studies have shown that inhibiting the activity of PROX1 with small molecules can be effective in treating neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Overall, PROX1 is a protein that is involved in a number of important signaling pathways that are involved in the development and maintenance of tissues and organs. Its dysfunction has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As such, it is a potential drug target, and further research is needed to understand its role in these diseases and to develop effective treatments.

Protein Name: Prospero Homeobox 1

Functions: Transcription factor involved in developmental processes such as cell fate determination, gene transcriptional regulation and progenitor cell regulation in a number of organs. Plays a critical role in embryonic development and functions as a key regulatory protein in neurogenesis and the development of the heart, eye lens, liver, pancreas and the lymphatic system. Involved in the regulation of the circadian rhythm. Represses: transcription of the retinoid-related orphan receptor RORG, transcriptional activator activity of RORA and RORG and the expression of RORA/G-target genes including core clock components: BMAL1, NPAS2 and CRY1 and metabolic genes: AVPR1A and ELOVL3

The "PROX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PROX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets